Non-selective muscarinic antagonist. Widely used clinically to treat motion sickness.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 384.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.6 mL||13.01 mL||26.02 mL|
|5 mM||0.52 mL||2.6 mL||5.2 mL|
|10 mM||0.26 mL||1.3 mL||2.6 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References are publications that support the products' biological activity.
Jones and Shannon (2000) Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. Eur.J.Pharmacol. 391 105 PMID: 10720641
Nakao et al (1999) Cerebral blood flow responses to somatosensory stimulation are unaffected by scopolamine in unanesthetized rat. J.Pharmacol.Exp.Ther. 290 929 PMID: 10411611
Parkes (1965) An examination of central actions characteristic of scopolamine: comparison of central and peripheral activity in scopolamine, atropine and some synthetic basic esters. Psychopharmacologia 7 1 PMID: 5830966
If you know of a relevant reference for Scopolamine hydrobromide, please let us know.
View Related Products by Product Action
Keywords: Scopolamine hydrobromide, supplier, Non-Selective, muscarinic, antagonist, Receptors, Acetylcholine, ACh, Non-selective, Muscarinics, Non-selective, Muscarinics, Tocris Bioscience
9 Citations for Scopolamine hydrobromide
Citations are publications that use Tocris products. Selected citations for Scopolamine hydrobromide include:
Chuhma et al (2014) Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Elife 81 901 PMID: 24559678
Field et al (2012) Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium. J Neurosci 32 6288 PMID: 22553034
Higley et al (2011) Cholinergic interneurons mediate fast VGluT3-dependent glutamatergic transmission in the striatum. PLoS One 6 e19155 PMID: 21544206
Chuhma et al (2009) Dopamine neuron glutamate cotransmission: frequency-dependent modulation in the mesoventromedial projection. Neuroscience 164 1068 PMID: 19729052
Mamaligas et al (2016) Nicotinic and opioid receptor regulation of striatal dopamine D2-receptor mediated transmission Scientific Reports 6 37834 PMID: 27886263
Saunders et al (2015) Corelease of acetylcholine and GABA from cholinergic forebrain neurons. Front Behav Neurosci 4 PMID: 25723967
Parent et al (2015) Cholinergic and ghrelinergic receptors and KCNQ channels in the medial PFC regulate the expression of palatability. Proc Natl Acad Sci U S A 9 284 PMID: 26578914
Shin et al (2015) Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. J Neurosci 112 8124 PMID: 26080439
Marcott et al (2014) Phasic dopamine release drives rapid activation of striatal D2-receptors. Neuron 84 164 PMID: 25242218
Do you know of a great paper that uses Scopolamine hydrobromide from Tocris? If so please let us know.
Scopolamine hydrobromide Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.